Navigation Links
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Date:11/4/2008

short stature associated with Turner Syndrome, treatment of children with growth failure due to inadequate secretion of endogenous growth hormone, and treatment of short stature in children born SGA with no catch-up growth by age 2. It is also indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:

1) Adult Onset: Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or

2) Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

According to current standards, confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.

Important Safety Information

Remember, your doctor is the main source of information about you and your health. Please consult your doctor if you have any questions about your health or your medication.

Norditropin(R) (somatropin [rDNA origin] injection) is used to treat children with growth failure caused by very low or no production of growth hormone. It is also used to treat adults who do not make enough growth hormone.

Do not use Norditropin(R) if you have any of the following conditions: an allergy to phenol or any other ingredients in the medicine; active cancer or other forms of tumor; acute critical illness due to certain types of heart or abdomen surgery, trauma, or acute respiratory failure.

Children should not use Norditropin(R) if they have any of the following conditions: closed epiphyses (closed bone growth plates
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
2. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
3. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. FDA Approves Fougeras Clotrimazole Cream USP 1%
6. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
7. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
8. Signalife Board Approves Merger
9. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... and commercialization of novel drugs in the,therapeutic ... today,announced that it was added to the ... reconstituted its comprehensive set of U.S. and,global ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC ... of plant extracts and pharmaceutical raw materials,for ... in China,announced today that its company information ... Market Access Program, an information distribution,service that ...
... to offer choice of two distinct drugs on ... separate drug-eluting stent platforms, NATICK, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... coronary artery disease. The,PROMUS Stent is a private-labeled XIENCE(TM) V ...
Cached Biology Technology:Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... two genetic variants that increase the risk of developing ... to the origin of this often very painful condition, ... life of sufferers. Details of the research, ... Genetics and the Nuffield Department of Obstetrics & Gynaecology, ...
... Hospital (MGH) researchers has developed a faster way to ... inactivation, repair or alteration. The report from the ... Nature Methods , describes a highly effective but less ... (ZFNs). "With our approach, called context-dependent assembly, ...
... the University of California, Riverside have identified components in ... cells and weaken their attraction to a chemical signal ... bone. The research could lead to new therapies ... of Manuela Martins-Green , a professor of cell ...
Cached Biology News:Genetic variants linked to increased risk of common gynecological disease 2MGH researchers develop faster method of engineering zinc-finger nucleases 2MGH researchers develop faster method of engineering zinc-finger nucleases 3UCR scientists identify pomegranate juice components that could stop cancer from spreading 2
...
...
Contains L-glutamine...
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Biology Products: